27 patents
Utility
Compositions of a polyorthoester and an organic acid excipient
19 Dec 23
Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an organic acid excipient, and a basic drug are described, along with related methods.
Thomas B. Ottoboni, Lee Ann Lynn Girotti
Filed: 22 Mar 21
Utility
Methods of use of emulsion formulations of an NK-1 receptor antagonist
5 Sep 23
Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration.
Thomas B. Ottoboni, Han Han
Filed: 2 Nov 22
Utility
Methods of Use of Emulsion Formulations of an NK-1 Receptor Antagonist
9 Mar 23
Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration.
Thomas B. Ottoboni, Han Han
Filed: 2 Nov 22
Utility
Compositions of a Polyorthoester and an Aprotic Solvent
8 Dec 22
Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an aprotic solvent, and a drug are described.
Thomas B. Ottoboni, Lee Ann Lynn Girotti
Filed: 10 Jan 22
Utility
Long-acting polymeric delivery systems
16 Aug 22
Compositions comprised of a delivery vehicle or delivery system and an active agent dispersed within the delivery vehicle or system, wherein the delivery vehicle or system contains a polyorthoester polymer and a polar aprotic solvent.
Thomas B. Ottoboni, Lee Ann Lynn Girotti
Filed: 21 Dec 20
Utility
Compositions of a polyorthoester and an aprotic solvent
22 Feb 22
Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an aprotic solvent, and a drug are described.
Thomas B. Ottoboni, Lee Ann Lynn Girotti
Filed: 17 Jul 19
Utility
Emulsion formulations of an NK-1 receptor antagonist and uses thereof
16 Nov 21
Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration.
Thomas B. Ottoboni, Han Han
Filed: 16 Mar 20
Utility
Pharmaceutical Composition Comprising Antiemetic Compounds and Polyorthoester
4 Nov 21
The present disclosure provides for sustained release pharmaceutical formulations which can deliver both a 5-hydroxytryptamine 3 (5HT3) receptor antagonist and a neurokinin-1 (NK1) receptor antagonist to a subject in need thereof.
Thomas B. Ottoboni, Lee Ann Lynn Girotti
Filed: 14 Dec 20
Utility
Long-acting Polymeric Delivery Systems
28 Oct 21
Compositions comprised of a delivery vehicle or delivery system and an active agent dispersed within the delivery vehicle or system, wherein the delivery vehicle or system contains a polyorthoester polymer and a polar aprotic solvent.
Thomas B. Ottoboni, Lee Ann Lynn Girotti
Filed: 9 Jul 21
Utility
Methods of Treating Nausea Utilizing Semi-solid Delivery Vehicle Compositions Comprising Granisetron
19 Aug 21
A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle.
Steven Y. Ng, Hui-Rong Shen, Jorge Heller
Filed: 26 Apr 21
Utility
Long-acting polymeric delivery systems
10 Aug 21
Compositions comprised of a delivery vehicle or delivery system and an active agent dispersed within the delivery vehicle or system, wherein the delivery vehicle or system contains a polyorthoester polymer and a polar aprotic solvent.
Thomas B. Ottoboni, Lee Ann Lynn Girotti
Filed: 21 Oct 16
Utility
Long-acting polymeric delivery systems
10 Aug 21
Compositions comprised of a delivery vehicle or delivery system and an active agent dispersed within the delivery vehicle or system, wherein the delivery vehicle or system contains a polyorthoester polymer and a polar aprotic solvent.
Thomas B. Ottoboni, Lee Ann Lynn Girotti
Filed: 12 Sep 17
Utility
Long-acting Polymeric Delivery Systems
22 Jul 21
Compositions comprised of a delivery vehicle or delivery system and an active agent dispersed within the delivery vehicle or system, wherein the delivery vehicle or system contains a polyorthoester polymer and a polar aprotic solvent.
Thomas B. Ottoboni, Lee Ann Lynn Girotti
Filed: 21 Dec 20
Utility
Compositions of a Polyorthoester and an Organic Acid Excipient
8 Jul 21
Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an organic acid excipient, and a basic drug are described, along with related methods.
Thomas B. Ottoboni, Lee Ann Lynn Girotti
Filed: 22 Mar 21
Utility
Methods of Use of Emulsion Formulations of Aprepitant
24 Jun 21
Disclosed herein are novel pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration.
Thomas B. Ottoboni, Han Han
Filed: 5 Mar 21
Utility
Methods of Use of Emulsion Formulations of an NK-1 Receptor Antagonist
10 Jun 21
Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration.
Thomas B. Ottoboni, Han Han
Filed: 19 Feb 21
Utility
Emulsion formulations of aprepitant
23 Mar 21
Disclosed herein are novel pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration.
Thomas B. Ottoboni, Han Han
Filed: 30 Oct 19
Utility
Long-acting polymeric delivery systems
26 Jan 21
Compositions comprised of a delivery vehicle or delivery system and an active agent dispersed within the delivery vehicle or system, wherein the delivery vehicle or system contains a polyorthoester polymer and a polar aprotic solvent.
Thomas B. Ottoboni, Lee Ann Lynn Girotti
Filed: 13 Jun 17
Utility
Methods of Treating Nausea Utilizing Semi-solid Delivery Vehicle Compositions Comprising Granisetron
30 Dec 20
A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle.
Steven Y. Ng, Hui-Rong Shen, Jorge Heller
Filed: 13 Sep 20
Utility
Emulsion Formulations of an NK-1 Receptor Antagonist and Uses Thereof
9 Dec 20
Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration.
Thomas B. Ottoboni, Han Han
Filed: 15 Mar 20